Intech Investment Management LLC Acquires 11,834 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE)

Intech Investment Management LLC increased its stake in Apogee Therapeutics, Inc. (NASDAQ:APGE) by 232.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 16,934 shares of the company’s stock after purchasing an additional 11,834 shares during the quarter. Intech Investment Management LLC’s holdings in Apogee Therapeutics were worth $767,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Wellington Management Group LLP increased its position in Apogee Therapeutics by 35.7% in the third quarter. Wellington Management Group LLP now owns 4,814,400 shares of the company’s stock worth $282,798,000 after buying an additional 1,267,451 shares in the last quarter. Janus Henderson Group PLC increased its holdings in Apogee Therapeutics by 4,018.9% in the 3rd quarter. Janus Henderson Group PLC now owns 469,557 shares of the company’s stock worth $27,586,000 after acquiring an additional 458,157 shares in the last quarter. Point72 Asset Management L.P. increased its holdings in Apogee Therapeutics by 162.7% in the 3rd quarter. Point72 Asset Management L.P. now owns 707,268 shares of the company’s stock worth $41,545,000 after acquiring an additional 438,036 shares in the last quarter. Barclays PLC raised its stake in Apogee Therapeutics by 369.2% during the 3rd quarter. Barclays PLC now owns 365,046 shares of the company’s stock worth $21,443,000 after acquiring an additional 287,243 shares during the period. Finally, Vestal Point Capital LP purchased a new position in Apogee Therapeutics during the third quarter valued at approximately $8,018,000. 79.04% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have recently issued reports on APGE. Canaccord Genuity Group began coverage on shares of Apogee Therapeutics in a research note on Monday, November 25th. They issued a “buy” rating and a $89.00 price objective for the company. Wedbush reissued an “outperform” rating and set a $90.00 price target on shares of Apogee Therapeutics in a report on Tuesday, March 11th. Citigroup began coverage on Apogee Therapeutics in a research note on Thursday, March 13th. They issued a “buy” rating and a $95.00 price objective for the company. Canaccord Genuity Group started coverage on Apogee Therapeutics in a research note on Monday, November 25th. They set a “buy” rating and a $89.00 target price on the stock. Finally, Guggenheim restated a “buy” rating on shares of Apogee Therapeutics in a research note on Monday, February 10th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $92.17.

Apogee Therapeutics Trading Down 1.3 %

NASDAQ:APGE opened at $39.84 on Monday. The business’s 50-day moving average is $37.46 and its 200 day moving average is $46.25. Apogee Therapeutics, Inc. has a 12 month low of $29.10 and a 12 month high of $70.56. The company has a market capitalization of $1.79 billion, a P/E ratio of -16.46 and a beta of 2.46.

Apogee Therapeutics (NASDAQ:APGE) last issued its quarterly earnings data on Monday, March 3rd. The company reported ($1.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.94) by ($0.25). On average, research analysts forecast that Apogee Therapeutics, Inc. will post -3.09 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Michael Thomas Henderson sold 15,000 shares of the stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $40.58, for a total value of $608,700.00. Following the completion of the transaction, the chief executive officer now owns 1,302,987 shares of the company’s stock, valued at approximately $52,875,212.46. This trade represents a 1.14 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Carl Dambkowski sold 4,085 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $46.94, for a total value of $191,749.90. Following the sale, the insider now directly owns 255,348 shares in the company, valued at $11,986,035.12. The trade was a 1.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 49,195 shares of company stock worth $2,026,392. Insiders own 36.10% of the company’s stock.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.